Testing Volume Is Growing Faster Than the Valuation Can Ignore
Natera, Inc. (NASDAQ:NTRA) is turning personalized cancer monitoring into a growing clinical service, but its valuation prices in much more than today’s test volumes. Its Signatera platform detects molecular residual disease through circulating tumor DNA, helping clinicians assess whether cancer remains or returns after treatment. The commercial opportunity depends on recurring clinical use, reimbursement, and dependable test economics, not merely a growing number of research collaborations.
The opportunity is expanding. In June, Reuters reported that Aveta Biomics would use Signatera in a late-stage head-and-neck cancer trial to assess molecular residual disease and treatment response. Natera is also building evidence in colorectal cancer, melanoma, and other indications.
Natera, Inc. ranks seventh among 11 Best Cancer Stocks to Invest In Now. The question for the ranking is whether its testing model can generate more sustainable profits than cancer-drug developers facing patent cliffs or regulatory binary events.
The Operating Results Support Growth, Not Yet the Multiple
Natera’s Q2 2026 revenue climbed 37.7% to $752.8 million, while gross margin rose to 64.5% from 63.4% a year earlier. Total tests processed increased 22.4% to about 1.04 million, and oncology tests jumped 57.2% to approximately 296,700. That mix shift toward oncology is important because repeat testing may increase revenue from an established patient relationship, although clinical necessity varies by disease and treatment plan.
Natera, Inc. narrowed its operating loss to $75.8 million from $110.4 million despite operating expenses rising to $555.3 million. Management raised full-year revenue guidance by $100 million at the midpoint to $2.85 billion–$2.91 billion and maintained expectations of positive cash flow for 2026. Reported revenue and gross profit also benefited from a $52.3 million change in revenue-accrual estimates, compared with a similar $45.3 million adjustment a year earlier. This distinction matters when assessing underlying margin improvement, since the full current-quarter adjustment should not be mistaken for incremental year-over-year profitability.
The stock’s growth narrative has drawn scrutiny. Jim Cramer’s discussion of Natera’s valuation after its rally describes the tension between attractive oncology adoption and paying far ahead of established earnings. The company’s performance is improving, but growth by itself does not establish an attractive entry valuation.
A High Sales Multiple Demands Durable Economics
The Seeking Alpha data gives no meaningful trailing or forward P/E for Natera, Inc., which remains loss-making. Instead, it shows trailing enterprise value to sales of 20.63 times and forward EV/sales of 19.20 times, versus a sector forward median of 3.61 times. Price-to-sales of 20.36 times is similarly elevated. These multiples imply expectations for years of strong expansion and eventual operating margins; they provide little cushion if growth moderates or payers reduce reimbursement.
Analyst consensus in the same data does not indicate a meaningful earnings multiple until 2028, when estimated P/E is 213.68 times, declining to 101.72 times in 2029. The estimated EPS growth rates of 6.85% for 2026 and 99.42% for 2027 should not be read as mature-company compounding rates while earnings are negative or near breakeven. The relevant measure is whether rising test gross profit can outpace research, commercialization, and administrative spending.
Natera had approximately $1.09 billion of cash at June 30 and reported $80.3 million of debt in its Q2 release. Cash reserves offer flexibility, but market capitalization near $56.7 billion means future growth, not balance-sheet liquidation value, drives investor returns. The much larger enterprise value primarily capitalizes years of expected testing profits.
Testing also has regulatory and evidence risk. Our coverage of the SINERGY study in head-and-neck cancer examines whether Signatera-guided treatment adjustments can improve clinical decision-making, a central step toward broader adoption. Trial use as a biomarker is not automatically the same as an FDA-approved indication or insurer reimbursement.
What Could Justify the Premium?
Wall Street has become more optimistic, though target increases do not guarantee performance. Canaccord raised its price target to $500 from $375 on October 19, while JPMorgan lifted its target to $460 from $360 on October 14. Barclays maintained Overweight but warned that diagnostics valuations already incorporate material upside.
According to Insider Monkey’s database, the number of hedge funds holding Natera, Inc. increased from 68 in Q1 to 77 in Q2 2026, reflecting broader institutional interest. However, these historical holdings do not indicate how investors responded to subsequent clinical developments. Short interest stood at 6.36 million shares at September 30, up from 5.51 million in August, or 4.54% of float.
Natera can justify a premium only if clinical evidence expands reimbursed volumes, high test margins convert into operating profit, and management keeps expense growth below revenue growth. The upside case has more substance than a speculative diagnostic platform, but the current sales multiple makes execution central to the stock’s risk.
READ NEXT: Grail (GRAL) vs Guardant Health (GH): Which is a Better Stock to Buy? and Billionaire Druckenmiller and Jim Cramer Like These Stocks.
Hedge Fund Resource Center